781 related articles for article (PubMed ID: 32464637)
1. The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system.
Offringa A; Montijn R; Singh S; Paul M; Pinto YM; Pinto-Sietsma SJ
Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):317-325. PubMed ID: 32464637
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
Datta PK; Liu F; Fischer T; Rappaport J; Qin X
Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
[TBL] [Abstract][Full Text] [Related]
3. Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2).
Zemlin AE; Wiese OJ
Ann Clin Biochem; 2020 Sep; 57(5):339-350. PubMed ID: 32369402
[TBL] [Abstract][Full Text] [Related]
4. Can a Combination of AT1R Antagonist and Vitamin D Treat the Lung Complication of COVID-19?
Rafiullah M
Am J Med Sci; 2020 Oct; 360(4):338-341. PubMed ID: 32736832
[TBL] [Abstract][Full Text] [Related]
5. Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers.
Danser AHJ; Epstein M; Batlle D
Hypertension; 2020 Jun; 75(6):1382-1385. PubMed ID: 32208987
[TBL] [Abstract][Full Text] [Related]
6. Can beta-adrenergic blockers be used in the treatment of COVID-19?
Vasanthakumar N
Med Hypotheses; 2020 Sep; 142():109809. PubMed ID: 32388480
[No Abstract] [Full Text] [Related]
7. Association of ACE2 receptor and ACEIs/ARBs with disease severity in COVID-19.
Sinha S; Sehgal A; Sehgal R
Drug Discov Ther; 2020; 14(4):161-170. PubMed ID: 32908071
[TBL] [Abstract][Full Text] [Related]
8. The renin-angiotensin-aldosterone system: Role in pathogenesis and potential therapeutic target in COVID-19.
Braga CL; Silva-Aguiar RP; Battaglini D; Peruchetti DB; Robba C; Pelosi P; Rocco PRM; Caruso-Neves C; Silva PL
Pharmacol Res Perspect; 2020 Aug; 8(4):e00623. PubMed ID: 32658389
[TBL] [Abstract][Full Text] [Related]
9. Drugs acting on renin angiotensin system and use in ill patients with COVID-19.
Alexandre J; Cracowski JL; Richard V; Bouhanick B;
Therapie; 2020; 75(4):319-325. PubMed ID: 32553503
[TBL] [Abstract][Full Text] [Related]
10. ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV.
Lubbe L; Cozier GE; Oosthuizen D; Acharya KR; Sturrock ED
Clin Sci (Lond); 2020 Nov; 134(21):2851-2871. PubMed ID: 33146371
[TBL] [Abstract][Full Text] [Related]
11. H
Yang G
Am J Physiol Cell Physiol; 2020 Aug; 319(2):C244-C249. PubMed ID: 32515982
[TBL] [Abstract][Full Text] [Related]
12. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.
Cheng H; Wang Y; Wang GQ
J Med Virol; 2020 Jul; 92(7):726-730. PubMed ID: 32221983
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19).
Bourgonje AR; Abdulle AE; Timens W; Hillebrands JL; Navis GJ; Gordijn SJ; Bolling MC; Dijkstra G; Voors AA; Osterhaus AD; van der Voort PH; Mulder DJ; van Goor H
J Pathol; 2020 Jul; 251(3):228-248. PubMed ID: 32418199
[TBL] [Abstract][Full Text] [Related]
14. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.
Malek Mahdavi A
Rev Med Virol; 2020 Sep; 30(5):e2119. PubMed ID: 32584474
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting.
Sharifkashani S; Bafrani MA; Khaboushan AS; Pirzadeh M; Kheirandish A; Yavarpour Bali H; Hessami A; Saghazadeh A; Rezaei N
Eur J Pharmacol; 2020 Oct; 884():173455. PubMed ID: 32745604
[TBL] [Abstract][Full Text] [Related]
16. Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS).
Cadegiani FA; Goren A; Wambier CG
Med Hypotheses; 2020 Oct; 143():110112. PubMed ID: 32721806
[TBL] [Abstract][Full Text] [Related]
17. Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2.
Young MJ; Clyne CD; Chapman KE
J Endocrinol; 2020 Nov; 247(2):R45-R62. PubMed ID: 32966970
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications.
Groß S; Jahn C; Cushman S; Bär C; Thum T
J Mol Cell Cardiol; 2020 Jul; 144():47-53. PubMed ID: 32360703
[TBL] [Abstract][Full Text] [Related]
19. Discovery and characterization of ACE2 - a 20-year journey of surprises from vasopeptidase to COVID-19.
Hooper NM; Lambert DW; Turner AJ
Clin Sci (Lond); 2020 Sep; 134(18):2489-2501. PubMed ID: 32990314
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of renin-angiotensin-aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis.
Greco A; Buccheri S; D'Arrigo P; Calderone D; Agnello F; Monte M; Milluzzo RP; Franchina AG; Ingala S; Capodanno D
Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):335-337. PubMed ID: 32671399
[No Abstract] [Full Text] [Related]
[Next] [New Search]
